Wells Fargo
BHVN

Wells Fargo’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Wells Fargo’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,544
Closed -$838K – 7973
2022
Q3 		$838K Sell
5,544
-2,805
-34% -$416K ﹤0.01% 3346
2022
Q2 		$1.22M Sell
8,349
-71,523
-90% -$9.14M ﹤0.01% 3165
2022
Q1 		$9.47M Sell
79,872
-21,636
-21% -$2.7M ﹤0.01% 1880
2021
Q4 		$14M Sell
101,508
-1,675,910
-94% -$213M ﹤0.01% 1603
2021
Q3 		$247M Buy
1,777,418
+346,231
+24% +$43.2M 0.05% 342
2021
Q2 		$139M Buy
1,431,187
+295,977
+26% +$24M 0.03% 526
2021
Q1 		$77.6M Buy
1,135,210
+137,173
+14% +$11.1M 0.02% 811
2020
Q4 		$85.5M Sell
998,037
-67,086
-6% -$5.68M 0.02% 712
2020
Q3 		$69.2M Buy
1,065,123
+179,306
+20% +$11.8M 0.02% 713
2020
Q2 		$64.8M Buy
885,817
+546,031
+161% +$29.1M 0.02% 732
2020
Q1 		$11.6M Buy
339,786
+306,285
+914% +$14M ﹤0.01% 1575
2019
Q4 		$1.82M Sell
33,501
-5,669
-14% -$281K ﹤0.01% 3414
2019
Q3 		$1.63M Buy
39,170
+5,995
+18% +$253K ﹤0.01% 3494
2019
Q2 		$1.45M Sell
33,175
-2,990
-8% -$169K ﹤0.01% 3605
2019
Q1 		$1.86M Sell
36,165
-3,809
-10% -$165K ﹤0.01% 3416
2018
Q4 		$1.48M Buy
39,974
+1,439
+4% +$51.9K ﹤0.01% 3531
2018
Q3 		$1.45M Buy
38,535
+807
+2% +$29.7K ﹤0.01% 3681
2018
Q2 		$1.49M Sell
37,728
-3,456
-8% -$110K ﹤0.01% 3689
2018
Q1 		$1.06M Buy
41,184
+11,373
+38% +$340K ﹤0.01% 3867
2017
Q4 		$805K Sell
29,811
-5,996
-17% -$165K ﹤0.01% 4072
2017
Q3 		$1.34M Buy
35,807
+9,594
+37% +$291K ﹤0.01% 3629
2017
Q2 		$655K Buy
+26,213
New +$604K ﹤0.01% 4044

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Wells Fargo's BHVN Position: Q4 2022 in Review

Wells Fargo sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 5,544 shares — an estimated $838K sold.

Wells Fargo first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $247M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Wells Fargo reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Wells Fargo sold 5,544 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $838K.
  • Wells Fargo first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Wells Fargo's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $247M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.